Probability is better than average I think mate, Robert Clark has a perfect record with FDA approvals and has been heavily involved for 2 years. I think if phase 2 data is strong, I think they will lodge for breakthrough therapy status and with some luck, that happens by the end of the year.
IHL Price at posting:
4.1¢ Sentiment: Buy Disclosure: Held